-The United States Agency for International Development (USAID) committed $2.3 million to purchase 4.8 million doses of malaria tablets from Swiss Pharma, a Nigerian pharmaceutical company.
-The initiative, facilitated through the President’s Malaria Initiative, aims to expand access to malaria treatments in Nigeria and West Africa.
-Swiss Pharma (Swipha) became the first pharmaceutical company in Nigeria and West Africa to obtain WHO prequalification for its sulfadoxine/pyrimethamine malaria tablets, a key treatment for preventing malaria during pregnancy.
-Less than 10% of medicines produced in sub-Saharan Africa meet international quality standards, affecting access to vital treatments like malaria medications.
-The achievement of WHO certification for Swipha is expected to boost local production capacity, improve healthcare in the region, and contribute to broader public health efforts.
Peoplesmind
